RxDoctor Payments Data

Imad Issawi, MD

Cardiovascular Disease · Flushing, MINPI 1174590228

Payments from drug & device makers

$3,099in general payments, 2019–2025

Across 165 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$527
  • Merck$465
  • AstraZeneca$245
  • Johnson & Johnson$226
  • Pfizer$211
  • Boehringer Ingelheim$184
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,06099%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,099 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$131,484
Medicare patients
214
Services billed
1,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$245,586
EntrestoSacubitril/Valsartan131$169,702
XareltoRivaroxaban43$49,273
JardianceEmpagliflozin24$33,543
VerquvoVericiguat13$13,842
BrilintaTicagrelor16$12,681
CorlanorIvabradine Hcl13$7,987
Rosuvastatin Calcium268$4,969
Flecainide Acetate77$4,608
Metoprolol Succinate216$3,783
Ranolazine ErRanolazine24$2,468
Propafenone Hcl ErPropafenone Hcl13$2,226
Amlodipine Besylate221$2,067
ClopidogrelClopidogrel Bisulfate94$1,956
Amiodarone Hcl86$1,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$245,586185 claims
NovartisEntresto$527$169,702131 claims
Johnson & JohnsonXarelto$226$49,27343 claims
Boehringer IngelheimJardiance$184$33,54324 claims
MerckVerquvo$465$13,84213 claims
AstraZenecaBrilinta$245$12,68116 claims
AmgenCorlanor$78$7,98713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Flushing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →